What GHK-Cu peptide is, and what the research examines

GHK-Cu, written various ways as GHK Cu, GHKCu, or just the copper peptide, is a naturally occurring complex: the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys) holding a divalent copper ion, Cu²⁺. It is among the most heavily studied peptide-metal complexes in the literature, and the copper is why. The peptide works as a carrier that keeps copper bound and bioavailable.

For laboratory research only. This page explains what GHK-Cu is and what the published literature has examined. It does not cover dosing or administration, is not guidance for use in people or animals, has not been evaluated by the FDA, and makes no therapeutic claims.

The discovery

GHK was first pulled from the albumin fraction of human plasma in the early 1970s, during work asking why plasma from younger donors behaved differently from older donors in liver-tissue culture. The active fraction turned out to be a three-amino-acid sequence, and its affinity for copper was pinned down soon after. That history shapes how the compound gets framed: GHK-Cu was not designed as a drug candidate and then screened. It was found as an endogenous complex and characterized afterward, which is why the literature around it runs unusually broad, and unusually old, next to most research peptides.

Five decades of publishing have left a large but uneven record. Some of it is careful cell-culture and biochemical characterization. Some of it is review writing that recirculates the same primary sources. Anyone approaching GHK-Cu should budget time to tell the two apart.

What the molecule actually is

GHK itself is three amino acids: glycine, histidine, lysine. On its own it is an unremarkable short peptide. What sets GHK-Cu apart is the histidine residue, which supplies a binding site that chelates Cu²⁺ with high affinity, giving a stable complex whose properties differ from either piece alone.

That complex occurs naturally in human plasma, and reported concentrations fall off substantially with age, an observation that drove much of the early interest and one reason the compound gets discussed under the banner of aging research rather than as a plain peptide.

The bound complex also carries GHK-Cu's most recognizable physical tell. In solution it is a distinct blue, and how deep that blue runs tracks the copper coordination. It makes a handy informal check: a GHK-Cu solution that has gone colorless, or drifted toward green or brown, is telling you something about the state of the material. It is no substitute for an assay, but it is the first thing an experienced hand looks at.

Why the copper is the point

Copper is an essential trace element and a required cofactor for a number of enzymes, several of them directly tied to connective tissue:

• Lysyl oxidase, which cross-links collagen and elastin fibers
• Superoxide dismutase, part of the cell's antioxidant defense
• Cytochrome c oxidase, in mitochondrial respiration

Free copper ions are reactive and kept under tight regulation in the body. A complex that carries copper in a bound state is therefore a useful experimental tool: it lets researchers introduce copper into a system in a controlled form and watch what changes, instead of dosing in a free metal salt.

What the literature studies

Most published GHK-Cu work sorts into three broad buckets. All of it is laboratory research, cell culture and preclinical models, and the findings differ a lot with concentration, exposure, and the system in use.

The extracellular matrix and collagen

The biggest body of work sits with the extracellular matrix. In cultured fibroblast models, GHK-Cu has been studied in connection with collagen-related gene expression and with the behavior of fibroblasts themselves, the cells that build and maintain matrix proteins. Since copper is a cofactor for lysyl oxidase, which cross-links collagen, the peptide-copper pairing gives a mechanistic reason to expect matrix effects, and that is where the literature clusters.

Skin models

Growing out of the matrix work, GHK-Cu shows up heavily in skin research, which is exactly why searches for it so often surface cosmetic and dermatological sources. In-vitro studies have looked at gene-expression profiles in cultured skin cells, including genes tied to matrix remodeling and repair. It is worth being precise here: these are cultured-cell readouts, not clinical outcomes, and a compound appearing in skin-research literature is not evidence of a cosmetic effect in people.

Hair-follicle models

In hair research, GHK-Cu has been examined in relation to dermal papilla cells in vitro, the cells at the base of the follicle that help regulate the hair-growth cycle. This too is cell-culture work, and the literature is exploratory rather than settled.

How it is handled at the bench

Consumer write-ups on GHK-Cu rarely describe the experimental conditions, and that is where most of the useful detail lives. A few practical points recur across the in-vitro literature.

Concentrations span orders of magnitude. Published cell-culture work runs from nanomolar to high-micromolar, and the direction of an effect is not always consistent across that range. A result reported without its concentration is close to meaningless, and comparing two papers that used different ranges is a common way secondary write-ups go wrong.

The model system drives the result. Primary fibroblasts, immortalized keratinocyte lines, dermal papilla cells, and full-thickness skin equivalents do not behave alike, and a finding in one is not evidence for another. When a review says "GHK-Cu increases X," it pays to trace back which system produced it.

Copper controls matter. Because the complex delivers copper, a well-built experiment separates the effect of the peptide-copper complex from the effect of copper itself, usually with a copper-salt comparator, and often a copper-free GHK arm as well. Studies without those arms cannot tell the two apart, a recurring weakness in the older literature.

Serum in the medium interferes. Copper binds avidly to serum albumin, which is how GHK-Cu was found in the first place, so serum-containing media muddy any copper-carrier experiment. Serum-free or defined-media conditions show up in the more careful work for exactly that reason.

"Copper peptide" as a category

"Copper peptide" gets used loosely, and the slack causes real confusion when you compare sources.

GHK-Cu is the copper peptide the research literature overwhelmingly means. Other copper-binding peptide complexes exist and crop up in cosmetic-chemistry contexts. AHK-Cu is the one you will meet most often, along with various proprietary copper tripeptide preparations marketed under trade names rather than sequences. These are different molecules, with different sequences and different published evidence, and a claim sourced from GHK-Cu work does not carry over to them.

When a source says "copper peptides" in the plural without naming a sequence, it is usually describing a formulation category, not a defined compound. For research the sequence is the compound, and anything without one cannot be sourced, verified, or replicated.

Research-grade GHK-Cu vs. cosmetic serums

A large share of GHK-Cu search interest comes from skincare, so it is worth stating plainly how that relates to research material, because the two are not interchangeable.

Cosmetic serums that contain copper tripeptide are finished consumer products. They are formulated at low concentrations in a vehicle meant for topical use, regulated as cosmetics, and manufactured to that standard. Their concentration is generally not disclosed as a measured figure, and they do not come with batch analytical documentation.

Research-grade GHK-Cu is a characterized reference compound, supplied with a batch Certificate of Analysis recording measured purity, and intended for in-vitro laboratory work. It is not formulated for application to skin, is not supplied for that, and is not a cosmetic.

We do not supply GHK-Cu for cosmetic or personal use, and material bought here should not be used that way. If what you want is a skincare product, the right thing to buy is a regulated cosmetic from a cosmetics manufacturer, and this is not it.

Where the "benefits" write-ups go wrong

Searches for the compound routinely return benefit lists. Read alongside the primary literature, three failure modes account for most of the gap between the two.

In-vitro findings get reported as outcomes. A shift in a gene's expression in cultured fibroblasts is a mechanistic observation in a dish. It is not a demonstrated effect in a person, and the distance between the two is the whole difficulty of translational research.

The concentration gets dropped. As above: a result at 10 µM in serum-free medium says nothing about what a formulation containing an undisclosed amount does on intact skin, where the stratum corneum is a serious barrier to a charged metal complex.

Reviews get cited as if they were experiments. A lot of the secondary GHK-Cu literature is reviews citing other reviews. Trace a claim back to its original experimental source and the list of things actually demonstrated tends to shrink.

None of this makes the compound uninteresting. It is one of the better-characterized peptide-metal complexes available, which is precisely why it is a useful research tool. It just means the research question and the marketing claim are two different things.

Stability, handling, and why format matters

Copper peptide complexes are more delicate than many short peptides, for a reason specific to the chemistry: the property under study depends on copper staying coordinated to the peptide. Anything that disturbs that coordination changes what is in the vial.

pH governs the coordination directly. GHK-Cu holds up across a moderate, near-neutral range and is disturbed outside it, which is why buffer choice is not an incidental detail in a GHK-Cu protocol.

Oxidation and light matter more than they would for a plain peptide, because a redox-active metal is in play. Copper cycling between oxidation states is the same chemistry that makes free copper reactive in biological systems.

Temperature applies as it does to any peptide in solution: cold storage slows degradation, and repeated warming and cooling is worse than steady cold.

This is where supply format has a practical payoff. Lyophilized powder has to be reconstituted by the end user, and reconstitution is the step where avoidable variability creeps in: water choice, added volume, mixing technique, and the wait before first use all differ from bench to bench. Our GHK-Cu ships as a pre-mixed solution at a known concentration, prepared and documented under controlled conditions, which removes that step. For comparative work across batches that matters more than it looks, since it is one fewer uncontrolled variable standing between the certificate and the experiment.

How to read a GHK-Cu certificate

A batch Certificate of Analysis is the only part of a supplier's claims you can actually check, so it is worth knowing what to look at.

• A measured purity, not a marketing figure. A COA should carry the value measured for that lot, not a generic "99%+" stamped across every batch.
• A batch identity that matches the vial. A certificate you cannot tie to the material in front of you documents someone else's material.
• The analytical method. HPLC is the expected purity assay; mass spectrometry confirms identity. A number with no method behind it is not evidence.
• A date. Peptide material is not stable forever, and an undated certificate cannot tell you where a lot sits in its life.

We publish recent certificates in our COA library so you can review the format before ordering rather than after, and the Certificate of Analysis guide walks through one line by line.

Why we don't publish dosing

We do not publish dosing, reconstitution-for-use, or administration guidance for GHK-Cu, and that is deliberate rather than an oversight. The material is supplied for in-vitro laboratory research and is not for human or veterinary use, so quantity guidance aimed at a person would be inconsistent with what is actually being sold.

Experimental concentrations for cell-culture work are specific to the model, the endpoint, and the protocol. They belong in the primary literature, not on a supplier's page.

What GHK-Cu is not

Because the compound circulates so widely in skincare talk, a few clarifications help anyone approaching it as a research material:

• It is not an approved medicine anywhere, has not been evaluated by the FDA, and is not supplied for human use.
• It is not the same as copper supplementation. The complex has properties distinct from copper salts, which is the entire point of studying it.
• Published in-vitro findings do not transfer cleanly to whole organisms. Concentration and delivery differ enormously between a culture dish and a living system.

How GHK-Cu ships in the United States

We ship GHK-Cu to US laboratories as a pre-mixed 60mg solution, with no reconstitution step, alongside a batch-specific Certificate of Analysis recording identity by mass spectrometry and purity by HPLC. Every compound is synthesized in our own UK laboratory rather than imported and repackaged, and each US batch is verified in a US laboratory before it ships. Orders are dispatched cold-chain from the warehouse that serves the United States, with tracked delivery across the country next business day, priced in US dollars and payable by Visa, Mastercard or Apple Pay. Store it refrigerated at 2-8°C on arrival, not frozen.

GHK-Cu is also a component in two multi-compound sets: the Glow Stack, where it is combined with BPC-157 and TB-500, and the KLOW blend, which adds KPV. If you need the concentration of a vial, the peptide calculator does the arithmetic. For full supply details, strengths, batch documentation, and dispatch, see the GHK-Cu product page.

Related reading

• What is the Glow Stack? · What are research peptides? · What is a Certificate of Analysis?